According to DelveInsight’s evaluation, the worldwide Glioblastoma development landscape includes over 200 major pharmaceutical organizations actively pursuing more than 220 therapeutic candidates, encompassing Clinical Trial evaluations, Treatment approaches, Mechanisms of Action, Administration Routes, and Pipeline Advancements.
This Glioblastoma Pipeline analysis encompasses thorough commercial and clinical evaluations of investigational products spanning from preclinical stages through commercialization. The document features comprehensive drug descriptions, encompassing mechanisms of action, clinical research programs, regulatory submissions (where applicable), and developmental activities including technological innovations, partnerships, mergers and acquisitions, financial backing, regulatory designations, and additional product-specific information.
DelveInsight’s “Glioblastoma Pipeline Insight, 2025” delivers extensive perspectives on the current clinical research landscape and expansion potential within the Glioblastoma therapeutic arena.
Key Highlights from the Glioblastoma Pipeline Analysis: https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr
- Pharmaceutical organizations worldwide are dedicating substantial efforts toward innovative Glioblastoma therapeutic development with notable achievements in recent years.
- Organizations advancing Glioblastoma treatments include Denovo BioPharma, Apogenix, Cantex, VAXIMM, Mustang Bio, J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, among others.
- Investigational Glioblastoma treatments across various clinical development stages include Enzastaurin, Asunercept, Azeliragon, VXM01, MB-101, JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and additional candidates anticipated to substantially influence the Glioblastoma marketplace in upcoming years.
- During November 2025, GenomOncology unveiled a strategic partnership with the Glioblastoma Foundation focused on advancing genomic testing for glioblastoma, the most aggressive brain malignancy in the U.S. Through this collaboration, the Foundation’s recently established genomic testing laboratory will integrate GenomOncology’s sophisticated Pathology Workbench (PWB) platform, substantially accelerating the delivery of genetic test results to patients.
- During June 2025, Diakonos Oncology, a U.S.-headquartered biotechnology company, secured $20 million through a private placement of Simple Agreements for Future Equity (SAFE) to expedite its Phase II glioblastoma trial of dubodencel. The capital will additionally support the extension of its clinical portfolio into additional indications, encompassing refractory melanoma. The funding round featured participation from new investors including Baylor College of Medicine and the Brain Tumor Investment Fund, alongside current investors, including the company’s CEO, Mike Wicks.
- During May 2025, According to a press announcement from Roswell Park Comprehensive Cancer Center, the Phase 2b SURVIVE study (NCT05163080) examining SurVaxM, a cancer vaccine, in patients with newly diagnosed glioblastoma will advance based on interim trial data evaluation.
- During November 2024, Maryland-headquartered biotechnology company Shuttle Pharma extended its Phase II trial of ropidoxuridine for glioblastoma, with the initial patient cohort now receiving treatment at cancer centers throughout the U.S.
- During November 2024, The Global Coalition for Adaptive Research (GCAR) established an agreement to evaluate AstraZeneca’s AZD1390 in the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) trial. This adaptive platform trial, incorporating response-adaptive randomization and a Phase II/III framework, is engineered to accelerate the discovery and validation of effective treatments for glioblastoma patients.
- During July 2024, The Ivy Brain Tumor Center at Barrow Neurological Institute in the U.S. commenced dosing for the first participant in the Phase III Gliofocus trial, examining the PARP1/2 selective inhibitor, niraparib, in adults with newly diagnosed MGMT-unmethylated glioblastoma.
- During May 2024, Moleculin Biotech announced the initiation of an investigator-initiated Phase II NU 21C06 clinical trial, backed by funding from the National Institutes of Health (NIH), to examine WP1066 in combination with radiation therapy for adults with glioblastoma.
- During February 2024, The Institute of Cancer Research (ICR) in London reported promising outcomes from a Phase I/II clinical trial of 2-OHOA, a novel drug derived from oleic acid, for the treatment of glioblastoma. Oleic acid, present naturally in animal and vegetable fats like olive oil, serves as the foundation for 2-OHOA, a synthetic lipid engineered to inhibit cancer cell growth by restructuring their abnormal membranes.
Glioblastoma Disease Overview
Glioblastoma, alternatively termed glioblastoma multiforme (GBM), represents a type of malignant brain tumor originating from astrocytes, a category of supportive cells in the brain. It constitutes the most aggressive and prevalent form of primary brain cancer in adults. Glioblastomas are highly infiltrative tumors, indicating they proliferate rapidly and invade surrounding brain tissue, rendering complete surgical removal challenging.
Request a Free Sample PDF to learn more about Glioblastoma Pipeline Therapeutic Assessment: https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr
Emerging Glioblastoma Compounds Across Various Clinical Development Phases Include:
- Enzastaurin: Denovo BioPharma
- Asunercept: Apogenix
- Azeliragon: Cantex
- VXM01: VAXIMM
- MB-101: Mustang Bio
- JIN 001: J INTS BIO
- CT 179: Curtana Pharmaceuticals
- PRT3645: Prelude Therapeutics
- CD200AR L: OX2 Therapeutics
- ADI-PEG 20: Polaris Group
- CM93: Crimson Biopharm
- Berubicin: CNS Pharmaceuticals
- SurVaxM: MimiVax
- BPM31510: Berg, LLC
- ASC40: Ascletis
- Enzastaurin: Denovo Biopharma
- Marizomib: Celgene Corporation
Glioblastoma Administration Routes
The Glioblastoma pipeline analysis presents therapeutic evaluation of developmental drugs by Administration Route. Products are classified under various routes including:
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Glioblastoma Molecular Classifications
Glioblastoma Products are organized under different Molecular types including:
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Glioblastoma Pipeline Therapeutic Evaluation
- Glioblastoma Classification by Product Category
- Glioblastoma By Development Phase and Product Category
- Glioblastoma Classification by Administration Route
- Glioblastoma By Development Phase and Administration Route
- Glioblastoma Classification by Molecular Type
- Glioblastoma by Development Phase and Molecular Type
DelveInsight’s Glioblastoma Report encompasses approximately 220+ products across different clinical development phases including:
- Late-phase products (Phase III)
- Mid-phase products (Phase II)
- Early-phase product (Phase I)
- Preclinical and Discovery phase candidates
- Discontinued & Inactive candidates
- Administration Routes
Access additional details on Glioblastoma products in the comprehensive report. Download the Glioblastoma pipeline report to discover more about emerging Glioblastoma therapies: https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr
Notable Organizations in the Glioblastoma Therapeutics Arena include:
Leading companies creating therapies for Glioblastoma include Array Biopharma, AstraZeneca, Doule bond Pharmaceuticals, Philogen, Immatics N.V, BioNTech, InovioPharma, Noxxon Pharma, Celgene Corporation, Karyo Pharma, Neugate Theranostics, Novartis, Orphelia Pharma, Merck, Acerta Pharma, Genenta Science, CNS Pharmaceutical, Pfizer, Roche, Oncotelic Therapeutics, Autotelic Therapeutics, ACADIA Pharmaceuticals, Mayo Clinic, Cytogel, Xgene Pharmaceutical, Ascletis, 3-V Biosciences, Yumanity Therapeutics, among others.
Glioblastoma Pipeline Evaluation:
The Glioblastoma pipeline document delivers insights into:
- Comprehensive information about organizations creating therapies for Glioblastoma treatment with combined therapeutic candidates developed by individual companies.
- Assessment of various therapeutic candidates organized into early-phase, mid-phase, and late-phase development for Glioblastoma Treatment.
- Glioblastoma leading companies engaged in targeted therapeutic development with corresponding active and inactive (dormant or discontinued) initiatives.
- Glioblastoma Drugs under investigation based on developmental phase, administration route, target receptor, monotherapy or combination therapy, various mechanisms of action, and molecular classifications.
- Comprehensive evaluation of partnerships (company-company collaborations and company-academia partnerships), licensing arrangements and financial details for future progression of the Glioblastoma marketplace.
The document is constructed utilizing data and intelligence gathered from the researcher’s proprietary databases, company/university platforms, clinical trial registries, conferences, SEC documents, investor materials, and highlighted press announcements from company/university platforms and industry-focused third-party resources.
Download Sample PDF Report to explore more about Glioblastoma drugs and therapies: https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr
Glioblastoma Pipeline Market Growth Factors
- Escalating incidence of Glioblastoma multiforme, advancing Healthcare Infrastructure, demand for Novel and Effective Drugs represent some of the significant factors stimulating the Glioblastoma Market.
Glioblastoma Pipeline Market Challenges
- Nevertheless, aggressive characteristics of GBM and the complexity of targeting the central nervous system, the current standard of care for patients with newly diagnosed glioblastoma demonstrates limited effectiveness and a second line has not been established and other factors are generating obstacles in the Glioblastoma Market expansion.
Scope of Glioblastoma Pipeline Drug Analysis
- Geographic Coverage: Global
- Key Glioblastoma Organizations: Denovo BioPharma, Apogenix, Cantex, VAXIMM, Mustang Bio, J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others
- Key Glioblastoma Treatments: Enzastaurin, Asunercept, Azeliragon, VXM01, MB-101, JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others
- Glioblastoma Therapeutic Classification: Glioblastoma currently marketed and Glioblastoma emerging treatments
- Glioblastoma Market Forces: Glioblastoma market growth factors and Glioblastoma market challenges
About DelveInsight
DelveInsight represents a premier Business Consultant and Market Research organization concentrated exclusively on life sciences. It supports Pharmaceutical companies by delivering comprehensive end-to-end solutions to enhance their performance. It additionally provides Healthcare Consulting Services, which contribute to market evaluation to accelerate business expansion and address challenges with a practical methodology.
Contact Information:
Kanishk
kkumar@delveinsight.com